The Irish Times

Concerns over cannabis drug product cost

National Centre for Pharmaco-Economics finds Sativex is not cost-effective

Thu Oct 09 2014 - 01:00

Patients are currently paying €500 a month for Fampridine

Mon Sept 29 2014 - 01:00

Fampyra had been provided free for 2½ years under clinical trial by manufacturer Biogen

Tue Jul 01 2014 - 09:44

Authorities said in 2012 Fampyra not demonstrably cost-effective for treatment of MS

Tue Jun 17 2014 - 01:05

Director of the National Centre for Pharmaco-economics says he has ‘real concerns’ about new generation of anti-coagulants

Tue Apr 30 2013 - 06:00